Regeneron Pharmaceuticals (REGN) said late Friday that the US Food and Drug Administration issued a complete response letter rejecting its request to add extended dosing intervals for Eylea HD injection 8 mg across all approved indications.
The company said the health agency raised no concerns about the drug's safety or efficacy but declined to approve the extended schedule.
The drugmaker said it is reviewing the decision and considering the next steps.
Eylea HD is approved to treat wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。